A first look, and it’s a pretty loud one
Sapience Therapeutics rolled into AACR with the first public clinical data for ST316, its first-in-class β-catenin antagonist. In the ongoing Phase 2 expansion study, 15 patients with second-line colorectal cancer were treated with ST316 plus FOLFIRI and bevacizumab, and the company says the combo delivered a 47% confirmed objective response rate.
That’s not just “nice.” It’s the kind of number that makes biotech investors do the little chair-scoot closer to the screen. Sapience also reported a 93% disease control rate, meaning 14 of the 15 patients had either stable disease or a partial response.
Why investors care
This is early, small-sample biotech territory, so nobody’s crowning a miracle drug yet. But the readout matters because it’s the first time the market gets a real peek at ST316’s clinical promise, and the response rate was said to compare favorably with historical anti-VEGF plus chemo studies in this setting.
A few details that make the story more interesting:
- Responses were seen in both RAS-mutated and RAS-wild type patients
- The drug also showed activity in patients with liver metastases
- It worked in patients who’d previously been treated with bevacizumab
The biotech classic: hope, data, and a very long runway
For a clinical-stage company, this is the part where science and stock price start awkwardly dancing. Positive early data can light a fire under a small-cap name like SPAXX, but investors will still want to see bigger numbers, longer follow-up, and whether the response holds up when more patients pile in.
Big picture: Sapience just gave the market a credible “watch this space” moment. In biotech, that’s often how the story starts before it becomes either a breakout or a cautionary tale.